Recursion CEO has 80K shares withheld for taxes

RECURSION PHARMACEUTICALS, INC.

Rhea-AI Filing Summary

RECURSION PHARMACEUTICALS, INC. (RXRX) reported that CEO and President Najat Khan had 80,498 shares of Class A Common Stock withheld on 2026-08-17. These shares were withheld by the company to satisfy tax withholding and remittance obligations related to the net settlement of restricted stock units, not sold in an open-market transaction. After this withholding, Khan directly holds 2,095,298 shares of Class A Common Stock.

Insider Trade Summary

Tax Withholding: 80,498 shares

Tax Withholding 1 txn

Insider Khan Najat

Role CEO and President

Type	Security	Shares	Price	Value
Tax Withholding	Class A Common Stock F1	80,498	$3.16	$254K

Holdings After Transaction: Class A Common Stock — 2,095,298 shares (Direct)

Footnotes (1)

1. F1. Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.

Key Figures

Shares withheld for taxes: 80,498 shares Price per share: $3.16 per share Shares held after transaction: 2,095,298 shares

3 metrics

Shares withheld for taxes 80,498 shares Shares of Class A Common Stock withheld on 2026-08-17 to satisfy tax obligations

Price per share $3.16 per share Value used for tax-withholding disposition of 80,498 shares

Shares held after transaction 2,095,298 shares Direct ownership of Class A Common Stock by Najat Khan after withholding

Key Terms

restricted stock units, net settlement, withheld by the Issuer

3 terms

restricted stock units financial

"in connection with the net settlement of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

net settlement financial

"in connection with the net settlement of restricted stock units"

withheld by the Issuer financial

"Represents shares that have been withheld by the Issuer to satisfy"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did RXRX CEO Najat Khan report in this Form 4 transaction?

Najat Khan reported that 80,498 RXRX shares of Class A Common Stock were withheld on 2026-08-17 to cover tax withholding obligations from net-settled restricted stock units, rather than being sold on the open market.

Was the RXRX Form 4 transaction an open-market sale of shares?

No. The Form 4 states the 80,498 shares were withheld by the issuer to satisfy tax withholding and remittance obligations tied to restricted stock units, not an open-market sale or discretionary disposition.

How many RXRX shares does CEO Najat Khan hold after this reported transaction?

After the transaction, Najat Khan directly holds 2,095,298 shares of Recursion Pharmaceuticals Class A Common Stock, according to the reported post-transaction ownership figure in the Form 4 filing.

What is the reported price per RXRX share in this Form 4 event?

The Form 4 lists a price of $3.16 per share for the 80,498 shares withheld to satisfy tax obligations. This reflects the value used for the tax-withholding disposition related to restricted stock units.

What does transaction code "F" mean in the RXRX Form 4 for Najat Khan?

Transaction code "F" indicates payment of tax liability by delivering or withholding securities. Here, 80,498 RXRX shares were withheld by the issuer to cover tax obligations from net-settled restricted stock units.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 05:45 PM Accepted by SEC EDGAR 08/18/2026 - 05:44 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Khan Najat

(Last) (First) (Middle)

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY UTAH 84101

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	08/17/2026		F(1)		80,498	D	$3.16	2,095,298	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.

Remarks:

	/s/ Jonathan Golightly, attorney-in-fact	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)